Belite Bio, Inc - ADR earnings per share and revenue
On Nov 10, 2025, BLTE reported earnings of -0.65 USD per share (EPS) for Q3 25, missing the estimate of -0.49 USD, resulting in a -30.71% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.67% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.55 USD, with revenue projected to reach -- USD, implying an decrease of -15.38% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Belite Bio, Inc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Belite Bio, Inc - ADR reported EPS of -$0.65, missing estimates by -30.71%, and revenue of $0.00, 0% as expectations.
How did the market react to Belite Bio, Inc - ADR's Q3 2025 earnings?
The stock price moved up 3.67%, changed from $113.19 before the earnings release to $117.34 the day after.
When is Belite Bio, Inc - ADR expected to report next?
The next earning report is scheduled for Mar 16, 2026.
What are the forecasts for Belite Bio, Inc - ADR's next earnings report?
Based on 8
analysts, Belite Bio, Inc - ADR is expected to report EPS of -$0.55 and revenue of -- for Q4 2025.